The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
Pharmaceutical agonists of peroxisome proliferator-activated receptors (PPARs) are widely used in the management of type 2 diabetes, chiefly as lipid-lowering agents and oral hypoglycaemic agents. Although most of the focus has been placed on their cardiovascular effects, both positive and negative,...
Saved in:
Main Authors: | M. C. Thomas, K. A. Jandeleit-Dahm, C. Tikellis |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2012/456529 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?
by: Ahmad Aljada, et al.
Published: (2009-01-01) -
Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
by: Jihan Youssef, et al.
Published: (2002-01-01) -
Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy
by: Shinji Kume, et al.
Published: (2008-01-01) -
Effect of Pesticides on Peroxisome Proliferator-Activated Receptors (PPARs) and Their Association with Obesity and Diabetes
by: J. Hernández-Valdez, et al.
Published: (2023-01-01) -
Peroxisome Proliferator-Activated Receptors in Lung Cancer
by: Venkateshwar G. Keshamouni, et al.
Published: (2007-01-01)